TD Cowen raised the firm’s price target on Medpace (MEDP) to $462 from $356 and keeps a Sell rating on the shares. The firm saidthe company’s preliminary 2026 outlook as well as cancels being “well-behaved” and pre-backlog pipeline value growth of 30% year-over-year is a positive sign for the company’s fundamental outlook.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: